CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL. (12th June 2019) - Jacobsen, E.; Ďuraš, J.; Ardeshna, K.; Cherry, M.; Offner, F.; Mayer, J.; Bijou, F.; Tani, M.; Musuraca, G.; Merli, M.; Marasca, R.; Weaver, D.T.; et al.